ESTRO 2024 - Abstract Book

S2464

Clinical - Urology

ESTRO 2024

[95% CI 26.9-36.5] in the FM group, p=0.031. The 5- year cumulative late grade ≥ 2 genitourinary toxicity was 37.4% [95% CI 30.7-43.3] in the non-FM group versus 35.7% [95% CI 30.7-40.2] in the FM group, p=0.880. The 5-year cumulative biochemical recurrence rate was 17.7% [95%CI 12.7-22.5] in the non-FM group versus 22.8% [95% CI 18.4-26.9] in the FM group, p=0.040.

Conclusion:

Contrary to other reports on the use of FMs, our results showed an increased risk for late grade ≥ 2 gastrointestinal toxicity and biochemical recurrence for the group treated with FMs. Beside the dosimetric impact of FMs-based EBRT, further investigation is warranted to understand the underlying biological reaction induced by FMs.

Keywords: Fiducial markers, Prostate, Long-term impact

1899

Digital Poster